SynthesisThe European journal of health economics : HEPAC : health economics in prevention and care2020
The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature.
Synthesis in The European journal of health economics : HEPAC : health economics in prevention and care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 4 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- COPD-patients' perspective on adherence to therapy and its integration into a systematic literature review.BMC pulmonary medicine · 2026Pooled it
- Efficacy and safety of oral proprietary Chinese medicines in the treatment of stable chronic obstructive pulmonary disease: a network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Pattern and associated factors of COVID-19 knowledge, attitude and practice (KAP) among COVID-19-comorbid patients: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- The impact of diabetes mellitus on the emergence of multi-drug resistant tuberculosis and treatment failure in TB-diabetes comorbid patients: a systematic review and meta-analysis.Frontiers in public health · 2023Pooled it
- Astegolimab for chronic obstructive pulmonary disease with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials.American journal of respiratory and critical care medicine · 2026Trial
- A Pilot Economic Evaluation of a Nature-Based Therapy for Chronic Obstructive Pulmonary Disease in Austria.International journal of environmental research and public health · 2026Trial
- Cost-effectiveness of a self-management maintenance programme following pulmonary rehabilitation: a UK randomised controlled trial for patients with chronic obstructive pulmonary disease.BMJ open respiratory research · 2025Trial
- Assessment of risk factors responsible for rapid deterioration of lung function over a period of one year in patients with chronic obstructive pulmonary disease.Scientific reports · 2021Trial
- Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2.International journal of chronic obstructive pulmonary disease · 2020Trial
- The Global Airways Unit: A Multidisciplinary Strategy for Early Diagnosis and Comorbidity Detection.World journal of otorhinolaryngology - head and neck surgery · 2026Review
- The Financial Burden of Prescribed Medications in COPD.CHEST pulmonary · 2026Article
- Effect of ventilatory support pressure during exercise on endurance time in patients with COPD: a systematic review.ERJ open research · 2026Review
- The Societal and Economic Burden of COPD in Saudi Arabia.Global journal on quality and safety in healthcare · 2026Article
- Observational
- Expiratory Muscle Strength Training in COPD Dysphagia Management: A Survey of Speech-Language Pathologists.Journal of clinical medicine · 2026Article
- A Phenomenological Qualitative Study of Primary Informal Caregiver of Chinese Patients with Advanced Stage COPD: An In-Depth Exploration of Experiences and Needs.International journal of chronic obstructive pulmonary disease · 2026Article
- Healthcare Costs and Trends of Multimorbidity in COPD Patients: A Population-Based Study in Singapore.International journal of chronic obstructive pulmonary disease · 2026Article
- Evaluation of Clinical Characteristics and Lung Function Trajectories in Young COPD Patients Within the General Population.International journal of chronic obstructive pulmonary disease · 2026Article
- Unmet Needs and New Opportunities in Chronic Obstructive Pulmonary Disease in Italy: A Narrative Review with Insights from the GULP Study.International journal of chronic obstructive pulmonary disease · 2026Review
- Development and Internal Validation of a Prediction Model for Major Cardiovascular and Respiratory Events in Chronic Obstructive Pulmonary Disease: Nationwide Primary Care Electronic Medical Records Cohort Study.Pragmatic and observational research · 2026Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo find the economic burden of COPD and to identify the key cost drivers in the management of COPD patients across different European countries.
backgroundCOPD is a major cause of mortality and morbidity and is associated with considerable economic burden on the individual and society. It limits the daily activities and working ability of the patients. METHODOLOGY: We conducted a systematic search of PUBMED, SCIENCE DIRECT, Cochrane CENTRAL, SCOPUS, Google Scholar and SAGE Premier Databases to find scientific research articles evaluating the cost of COPD management from patient and societal perspective.
resultsEstimated per patient per year direct cost in Norway, Denmark, Germany, Italy, Sweden, Greece, Belgium, and Serbia was €10,701, €9580, €7847, €7448, €7045, €2896, €1963, and €2047, respectively. Annual per patient cost of work productivity loss was highest in Germany as €5735 and lowest in Greece as €998. It was estimated as €4824, €2033 and €1298 in Bulgaria, Denmark and Sweden, respectively. Several factors found associated with increasing cost of COPD management that include but not limited to late diagnosis, severity of disease, frequency of exacerbation, hospital readmissions, non-adherence to the therapy and exposure to COPD risk factors.
conclusionMinimizing the COPD exacerbations and controlling the worsening of symptoms may potentially reduce the cost of COPD management at any stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.